You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCyclobenzaprine
Accession NumberDB00924  (APRD00213)
TypeSmall Molecule
GroupsApproved
Description

Cyclobenzaprine is a skeletal muscle relaxant and a central nervous system (CNS) depressant. Cyclobenzaprine acts on the locus coeruleus where it results in increased norepinephrine release, potentially through the gamma fibers which innervate and inhibit the alpha motor neurons in the ventral horn of the spinal cord. It is structurally similar to Amitriptyline, differing by only one double bond.

Structure
Thumb
Synonyms
(3-Dibenzo[a,d]cyclohepten-5-ylidene-propyl)-dimethyl-amine
Ciclobenzaprina
Cyclobenzaprine
Cyclobenzaprinum
N,N-Dimethyl-5H-dibenzo(a,D)cycloheptene-delta(5,gamma)-propylamine
N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Δ5,γ-propylamine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-cyclobenzaprine - Tab 10mgtablet10 mgoralAltimed Pharma Inc.1995-12-312005-05-27Canada
Amrixcapsule, extended release15 mg/1oralSTAT Rx USA LLC2007-10-01Not applicableUs
Amrixcapsule, extended release15 mg/1oralPhysicians Total Care, Inc.2009-04-16Not applicableUs
Amrixcapsule, extended release30 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2007-10-01Not applicableUs
Amrixcapsule, extended release15 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-01-03Not applicableUs
Amrixcapsule, extended release30 mg/1oralRebel Distributors Corp2007-10-01Not applicableUs
Amrixcapsule, extended release15 mg/1oralRebel Distributors Corp.2007-10-01Not applicableUs
Amrixcapsule, extended release30 mg/1oralCephalon, Incorporated2007-10-01Not applicableUs
Amrixcapsule, extended release30 mg/1oralSTAT Rx USA LLC2007-10-01Not applicableUs
Amrixcapsule, extended release15 mg/1oralCephalon, Incorporated2007-10-01Not applicableUs
Auro-cyclobenzaprinetablet10 mgoralAuro Pharma Inc2011-06-15Not applicableCanada
Ava-cyclobenzaprinetablet10 mgoralAvanstra Inc2011-10-112014-08-21Canada
Cyclobenzaprinetablet10 mgoralSanis Health Inc2010-02-25Not applicableCanada
Cyclobenzaprinetablet10 mgoralSorres Pharma Inc2009-06-222014-06-20Canada
Cyclobenzaprinetablet10 mgoralSivem Pharmaceuticals Ulc2014-10-01Not applicableCanada
Cyclobenzaprine-10 - Tab 10mgtablet10 mgoralPro Doc Limitee1997-01-15Not applicableCanada
Dom-cyclobenzaprinetablet10 mgoralDominion Pharmacal1998-10-22Not applicableCanada
Flexeril -(10mg)tablet10 mgoralJanssen Inc1978-12-312005-08-04Canada
Jamp-cyclobenzaprinetablet10 mgoralJamp Pharma CorporationNot applicableNot applicableCanada
Jamp-cyclobenzaprinetablet10 mgoralJamp Pharma Corporation2011-10-18Not applicableCanada
Mylan-cyclobenzaprinetablet10 mgoralMylan Pharmaceuticals Ulc1997-05-21Not applicableCanada
Novo-cycloprinetablet10 mgoralTeva Canada Limited1994-12-31Not applicableCanada
Nu-cyclobenzaprine-tab 10mgtablet10 mgoralNu Pharm Inc1995-12-312012-09-04Canada
PHL-cyclobenzaprinetablet10 mgoralPharmel Inc2004-04-06Not applicableCanada
PMS-cyclobenzaprine - Tab 10mgtablet10 mgoralPharmascience Inc1996-12-31Not applicableCanada
Q-cyclobenzaprinetablet10 mgoralQd Pharmaceuticals Ulc2012-02-032015-08-21Canada
Ratio-cyclobenzaprinetablet10 mgoralRatiopharm Inc Division Of Teva Canada Limited1997-12-162015-10-26Canada
Riva-cyclobenzaprinetablet10 mgoralLaboratoire Riva Inc2000-05-23Not applicableCanada
Zym-cyclobenzaprinetablet10 mgoralZymcan Pharmaceuticals Inc2012-05-282014-06-16Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-cyclobenzaprine - Tab 10mgtablet10 mgoralApotex Inc1995-12-31Not applicableCanada
Comfort Pac With CyclobenzaprinekitPd Rx Pharmaceuticals, Inc.2013-07-15Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralMajor Pharmaceuticals1988-02-29Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralPharmaceutica North America, Inc.2013-08-07Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralNorthwind Pharmaceuticals, LLC2014-11-24Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralGolden State Medical Supply, Inc.2006-02-03Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralbryant ranch prepack2010-02-18Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralRed Pharm Drug Inc.2010-02-18Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated7.5 mg/1oralPreferred Pharmaceuticals, Inc.2015-05-01Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralCamber Pharmaceuticals2012-04-02Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralKAISER FOUNDATION HOSPITALS2010-03-02Not applicableUs
Cyclobenzaprine Hydrochloridetablet7.5 mg/1oralAidarex Pharmaceuticals LLC2011-08-29Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralMedsource Pharmaceuticals2012-04-02Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralBreckenridge Pharmaceutical, Inc.2006-12-06Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralPhysicians Total Care, Inc.1997-03-17Not applicableUs
Cyclobenzaprine Hydrochloridetablet7.5 mg/1oralDIRECT RX2014-01-01Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralAmerican Health Packaging2009-10-14Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralSolubiomix2015-08-262016-04-05Us
Cyclobenzaprine Hydrochloridetablet10 mg/1oralBlenheim Pharmacal, Inc.2010-01-25Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralWatson Laboratories, Inc.2006-02-03Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralPliva Inc.1995-09-29Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralREMEDYREPACK INC.2014-08-01Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-02-28Not applicableUs
Cyclobenzaprine Hydrochloridetablet7.5 mg/1oralProficient Rx LP2011-08-29Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralAurobindo Pharma Limited2008-09-26Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralCitron Pharma LLC2008-09-26Not applicableUs
Cyclobenzaprine Hydrochloridetablet5 mg/1oralSTAT Rx USA LLC2010-04-29Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-02-28Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralPd Rx Pharmaceuticals, Inc.2014-07-31Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/301oralNorthwind Pharmaceuticals2014-05-16Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Cyclobenzaprine Hydrochloridetablet5 mg/1oralJUBILANT CADISTA PHARMACEUTICALS, INC.2006-04-04Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralRanbaxy Pharmaceuticals Inc2008-05-12Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralRed Pharm Drug Inc.2010-07-12Not applicableUs
Cyclobenzaprine Hydrochloridetablet7.5 mg/1oralPreferred Pharmaceuticals, Inc.2012-05-08Not applicableUs
Cyclobenzaprine Hydrochloridetablet5 mg/1oralCamber Pharmaceuticals2012-04-02Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralLiberty Pharmaceuticals, Inc.1989-05-03Not applicableUs
Cyclobenzaprine Hydrochloridetablet5 mg/1oralLake Erie Medical DBA Quality Care Products LLC2006-04-04Not applicableUs
Cyclobenzaprine Hydrochloridetablet5 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-02Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralREMEDYREPACK INC.2014-02-06Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralPd Rx Pharmaceuticals, Inc.2010-02-18Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralProficient Rx LP2012-03-14Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralAmneal Pharmaceuticals of New York, LLC2010-02-18Not applicableUs
Cyclobenzaprine Hydrochloridetablet5 mg/1oralKeltman Pharmaceuticals Inc.2010-06-10Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralSTAT Rx USA LLC2010-02-18Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-02-28Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralPd Rx Pharmaceuticals, Inc.2014-07-31Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralMylan Institutional Inc.1997-08-25Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralJUBILANT CADISTA PHARMACEUTICALS, INC.2006-04-06Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated7.5 mg/1oralRanbaxy Pharmaceuticals Inc2008-05-12Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralRed Pharm Drug Inc.2007-01-01Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralPreferred Pharmaceuticals, Inc.2014-02-26Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralPreferred Pharmaceuticals Inc.2016-04-13Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralREMEDYREPACK INC.2013-03-13Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralMylan Pharmaceuticals Inc.2006-02-03Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralLake Erie Medical DBA Quality Care Product LLC2010-07-01Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralREMEDYREPACK INC.2013-05-22Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralProficient Rx LP1989-05-03Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralAmneal Pharmaceuticals of New York, LLC2010-02-18Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralKeltman Pharmaceuticals Inc.2006-08-24Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated7.5 mg/1oralKLE 2, Inc.2011-08-292015-12-29Us
Cyclobenzaprine Hydrochloridetablet10 mg/1oralApotheca Inc.2012-04-02Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralQualitest Pharmaceuticals2007-02-28Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralPd Rx Pharmaceuticals, Inc.2006-12-06Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralUnit Dose Services2007-02-28Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralRanbaxy Pharmaceuticals Inc2008-05-12Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralContract Pharmacy Services Pa2010-04-23Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralPreferred Pharmaceuticals, Inc.2015-04-22Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-02-28Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated7.5 mg/1oralMylan Pharmaceuticals Inc.2013-04-24Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-04-23Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralREMEDYREPACK INC.2012-03-05Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralREMEDYREPACK INC.2013-06-09Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralPd Rx Pharmaceuticals, Inc.2010-05-24Not applicableUs
Cyclobenzaprine Hydrochloridetablet5 mg/1oralDIRECT RX2014-01-01Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralReady Meds2010-02-18Not applicableUs
Cyclobenzaprine Hydrochloridetablet7.5 mg/1oralDispensing Solutions, Inc.2011-08-29Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralKvk Tech, Inc.2014-07-31Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralQualitest Pharmaceuticals2007-02-28Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralPd Rx Pharmaceuticals, Inc.2010-02-18Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralUnit Dose Services2007-02-28Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralMutual Pharmaceutical1995-05-23Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralNew Horizon Rx Group, LLC2013-08-25Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated7.5 mg/1oralProficient Rx LP2015-03-25Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralDispensing Solutions, Inc.1989-05-03Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralPreferred Pharmaceuticals, Inc.2011-07-07Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralA S Medication Solutions2007-02-28Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralRebel Distributors2010-02-18Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralMylan Pharmaceuticals Inc.1991-05-30Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-04-02Not applicableUs
Cyclobenzaprine Hydrochloridetablet5 mg/1oralREMEDYREPACK INC.2011-04-26Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralREMEDYREPACK INC.2013-03-18Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralCardinal Health2011-07-15Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated7.5 mg/1oralDIRECT RX2015-01-01Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2007-02-28Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralDispensing Solutions, Inc.2007-02-28Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralMc Kesson Contract Packaging2011-09-29Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralKvk Tech, Inc.2014-07-31Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralWatson Laboratories, Inc.1989-05-03Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralSTAT Rx USA LLC2010-04-29Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralMutual Pharmaceutical1995-05-23Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralClinical Solutions Wholesale2007-02-28Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralProficient Rx LP2012-04-02Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralMed Vantx, Inc.1995-09-29Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralLegacy Pharmaceutical Packaging2012-04-02Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated7.5 mg/1oralAll Pharma, Llc2015-03-25Not applicableUs
Cyclobenzaprine Hydrochloridetablet5 mg/1oralRebel Distributors2006-04-19Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralBlenheim Pharmacal, Inc.2012-03-30Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralNorthwind Pharmaceuticals, LLC2015-03-17Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralREMEDYREPACK INC.2014-10-29Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralbryant ranch prepack2007-02-28Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralAphena Pharma Solutions Tennessee, Llc1989-05-03Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated7.5 mg/1oralSa3, Llc2015-03-25Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralAidarex Pharmaceuticals LLC2010-02-18Not applicableUs
Cyclobenzaprine Hydrochloridetablet5 mg/1oralKAISER FOUNDATION HOSPITALS2015-11-10Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralRx Change Co.2014-11-06Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated7.5 mg/1oralMedsource Pharmaceuticals2011-08-29Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralREMEDYREPACK INC.2013-02-25Not applicableUs
Cyclobenzaprine Hydrochloridetablet5 mg/1oralPhysicians Total Care, Inc.2006-05-01Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralDIRECT RX2014-01-01Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2007-06-14Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralAmerican Health Packaging2014-05-30Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/10mgoralAlivio Medical Products, Llc2015-10-01Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated5 mg/1oralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated7.5 mg/1oralWatson Laboratories, Inc.2006-02-03Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralSTAT Rx USA LLC2010-04-29Not applicableUs
Cyclobenzaprine Hydrochloridetablet5 mg/1oralAv Pak2014-06-10Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated7.5 mg/1oralAidarex Pharmaceuticals LLC2015-03-25Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralClinical Solutions Wholesale2010-02-18Not applicableUs
Cyclobenzaprine Hydrochloridetablet10 mg/1oralProficient Rx LP2010-02-18Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralAurobindo Pharma Limited2008-09-26Not applicableUs
Cyclobenzaprine Hydrochloridetablet5 mg/1oralLegacy Pharmaceutical Packaging2012-04-02Not applicableUs
Cyclobenzaprine Hydrochloridetablet, film coated10 mg/1oralCitron Pharma LLC2008-09-26Not applicableUs
Cyclobenzaprine Hydrochloride KitkitPharmaceutica North America, Inc.2013-08-28Not applicableUs
Cyclobenzaprine Hyrochloridetablet7.5 mg/1oralbryant ranch prepack2011-08-29Not applicableUs
Cyclobenzaprine Hyrochloridetablet7.5 mg/1oralRebel Distributors Corp2011-08-29Not applicableUs
Cyclobenzaprine Hyrochloridetablet7.5 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-08-29Not applicableUs
Cyclobenzaprine Hyrochloridetablet7.5 mg/1oralH.J. Harkins Company, Inc.2011-08-29Not applicableUs
Cyclobenzaprine Hyrochloridetablet7.5 mg/1oralUnit Dose Services2011-08-29Not applicableUs
Fexmidtablet, film coated7.5 mg/1oralVictory Pharma, Inc.2008-11-01Not applicableUs
Fexmidtablet, film coated7.5 mg/1oralShionogi Inc.2011-10-01Not applicableUs
Fexmidtablet, film coated7.5 mg/1oralRebel Distributors Corp2008-11-01Not applicableUs
Fexmidtablet, film coated7.5 mg/1oralSTAT Rx USA LLC2008-11-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TabradolkitoralFusion Pharmaceuticals LLC2009-09-17Not applicableUs
TabradolkitoralCalifornia Pharmaceuticals, Llc2016-01-01Not applicableUs
International Brands
NameCompany
FlexerilJanssen
FlexibanSIT
Brand mixtures
NameLabellerIngredients
Cyclo/magLiving Well Pharmacy, Inc.
Cyclo/mag 10mg/200mgLiving Well Pharmacy, Inc.
Gapeam BudibacAlvix Laboratories, LLC
Therabenzaprine-60Physician Therapeutics Llc
Therabenzaprine-90Physician Therapeutics Llc
Therabenzaprine-90-5Physician Therapeutics Llc
Salts
Name/CASStructureProperties
Cyclobenzaprine Hydrochloride
6202-23-9
Thumb
  • InChI Key: VXEAYBOGHINOKW-UHFFFAOYSA-N
  • Monoisotopic Mass: 311.144077416
  • Average Mass: 311.848
DBSALT000479
Categories
UNII69O5WQQ5TI
CAS number303-53-7
WeightAverage: 275.3874
Monoisotopic: 275.167399677
Chemical FormulaC20H21N
InChI KeyInChIKey=JURKNVYFZMSNLP-UHFFFAOYSA-N
InChI
InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3
IUPAC Name
dimethyl(3-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-ylidene}propyl)amine
SMILES
CN(C)CCC=C1C2=CC=CC=C2C=CC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene connected by a cycloheptene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassDibenzocycloheptenes
Sub ClassNot Available
Direct ParentDibenzocycloheptenes
Alternative Parents
Substituents
  • Dibenzocycloheptene
  • Tertiary aliphatic amine
  • Tertiary amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor use as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.
PharmacodynamicsCyclobenzaprine, closely related to the antidepressant amitriptyline, is used as a skeletal muscle relaxant to reduce pain and tenderness and improve mobility. Unlike dantrolene, cyclobenzaprine cannot be used to treat muscle spasm secondary to cerebral or spinal cord disease.
Mechanism of actionLike other tricyclic antidepressants, cyclobenzaprine exhibits anticholinergic activity, potentiation of norepinephrine, and antagonism of reserpine. Cyclobenzaprine does not directly act on the neuromuscular junction or the muscle but relieves muscle spasms through a central action, possibly at the brain stem level. Cyclobenzaprine binds to the serotonin receptor and is considered a 5-HT2 receptor antagonist that reduces muscle tone by decreasing the activity of descending serotonergic neurons.
Related Articles
AbsorptionSlowly but well absorbed after oral administration
Volume of distributionNot Available
Protein bindingVery high (93%)
Metabolism

Extensively metabolized (gastrointestinal and hepatic).

SubstrateEnzymesProduct
Cyclobenzaprine
desmethylcyclobenzaprineDetails
Route of eliminationCyclobenzaprine is extensively metabolized, and is excreted primarily as glucuronides via the kidney.
Half life18 hours (range 8-37 hours)
Clearance
  • 0.7 L/min
ToxicityOral mouse and rat LD50 are 338 mg/kg and 425 mg/kg respectively. Signs of overdose include agitation, coma, confusion, congestive heart failure, convulsions, dilated pupils, disturbed concentration, drowsiness, hallucinations, high or low temperature, increased heartbeats, irregular heart rhythms, muscle stiffness, overactive reflexes, severe low blood pressure, stupor, and vomiting.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9941
Blood Brain Barrier+0.9512
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7567
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.6447
Renal organic cation transporterInhibitor0.7955
CYP450 2C9 substrateNon-substrate0.7826
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7501
CYP450 1A2 substrateInhibitor0.7324
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8933
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9158
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6955
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8127
BiodegradationNot ready biodegradable0.8727
Rat acute toxicity2.9697 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7531
hERG inhibition (predictor II)Inhibitor0.6767
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Anesta ag
  • Actavis totowa llc
  • Aurobindo pharma ltd
  • Cadista pharmaceuticals inc
  • Invagen pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Orit laboratories llc
  • Pliva inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
  • Mcneil pediatrics
Packagers
Dosage forms
FormRouteStrength
Capsule, extended releaseoral15 mg/1
Capsule, extended releaseoral30 mg/1
Tabletoral10 mg
Kit
Tabletoral10 mg/1
Tabletoral10 mg/10mg
Tabletoral5 mg/1
Tabletoral7.5 mg/1
Tablet, film coatedoral10 mg/301
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral5 mg/1
Tablet, film coatedoral7.5 mg/1
Kit
Kittopical
Kitoral
Prices
Unit descriptionCostUnit
Cyclobenzaprine hcl crystal273.88USD g
Cyclobenzaprine hcl powder35.84USD g
Fexmid 7.5 mg tablet4.18USD tablet
Flexeril 5 mg tablet2.04USD tablet
Flexeril 10 mg tablet1.74USD tablet
Cyclobenzaprine HCl 5 mg tablet1.71USD tablet
Cyclobenzaprine 5 mg tablet1.64USD tablet
Cyclobenzaprine HCl 10 mg tablet0.47USD tablet
Cyclobenzaprine 10 mg tablet0.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7387793 No2005-02-262025-02-26Us
US7544372 No2003-11-142023-11-14Us
US7790199 No2003-11-142023-11-14Us
US7820203 No2003-11-142023-11-14Us
US7829121 No2003-11-142023-11-14Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
boiling point173-177Not Available
water solubilityFreely SolubleNot Available
logP5.2Not Available
pKa8.47Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00689 mg/mLALOGPS
logP4.73ALOGPS
logP4.61ChemAxon
logS-4.6ALOGPS
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity102.62 m3·mol-1ChemAxon
Polarizability32.95 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Villani, F.J.; US. Patent 3,409,640; November 5,1968; assigned to Schering Corporation.

General ReferencesNot Available
External Links
ATC CodesM03BX08
AHFS Codes
  • 12:20.00
PDB EntriesNot Available
FDA labelDownload (230 KB)
MSDSDownload (73.1 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of Cyclobenzaprine can be increased when it is combined with 1,10-Phenanthroline.
3,4-DichloroisocoumarinThe serum concentration of Cyclobenzaprine can be increased when it is combined with 3,4-Dichloroisocoumarin.
3,4-MethylenedioxyamphetamineCyclobenzaprine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineCyclobenzaprine may increase the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Cyclobenzaprine can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
4-MethoxyamphetamineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Cyclobenzaprine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with 7-Nitroindazole.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINECyclobenzaprine may increase the serotonergic activities of 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.
AbirateroneThe serum concentration of Cyclobenzaprine can be increased when it is combined with Abiraterone.
AcenocoumarolCyclobenzaprine may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Aceprometazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Acetophenazine.
adipiplonThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with adipiplon.
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Cyclobenzaprine.
AgomelatineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Cyclobenzaprine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Cyclobenzaprine.
AlogliptinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Alogliptin.
Alpha-1-proteinase inhibitorThe serum concentration of Cyclobenzaprine can be increased when it is combined with Alpha-1-proteinase inhibitor.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cyclobenzaprine.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Cyclobenzaprine.
AmiodaroneThe metabolism of Cyclobenzaprine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Amperozide.
AmphetamineCyclobenzaprine may increase the stimulatory activities of Amphetamine.
AmprenavirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Amprenavir.
Antithrombin III humanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Antithrombin III human.
ApixabanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Apixaban.
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Cyclobenzaprine.
ApraclonidineThe therapeutic efficacy of Apraclonidine can be decreased when used in combination with Cyclobenzaprine.
AprepitantThe serum concentration of Cyclobenzaprine can be increased when it is combined with Aprepitant.
AprotininThe serum concentration of Cyclobenzaprine can be increased when it is combined with Aprotinin.
ArbutamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Arbutamine.
ArformoterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Arformoterol.
ArgatrobanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Argatroban.
AripiprazoleThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Aripiprazole.
ArtemetherThe metabolism of Cyclobenzaprine can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Asenapine.
AsunaprevirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Asunaprevir.
AtazanavirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Atazanavir.
AtomoxetineThe metabolism of Cyclobenzaprine can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Azaperone.
AzelastineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Cyclobenzaprine.
AzithromycinThe metabolism of Cyclobenzaprine can be decreased when combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Baclofen.
BambuterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bambuterol.
BarbitalThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Barbital.
BatimastatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Batimastat.
BenazeprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Benazepril.
BenmoxinCyclobenzaprine may increase the serotonergic activities of Benmoxin.
BenzamidineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Benzamidine.
BenzocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Benzocaine.
BenzphetamineCyclobenzaprine may increase the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Benzyl alcohol.
BetaxololThe metabolism of Cyclobenzaprine can be decreased when combined with Betaxolol.
BethanidineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Cyclobenzaprine.
BexaroteneThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Bexarotene.
BifeprunoxThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bifeprunox.
BivalirudinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Bivalirudin.
BoceprevirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Cyclobenzaprine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Cyclobenzaprine.
BromazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bromazepam.
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Cyclobenzaprine.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cyclobenzaprine.
BrompheniramineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Cyclobenzaprine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Cyclobenzaprine.
BupropionThe metabolism of Cyclobenzaprine can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Cyclobenzaprine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Cyclobenzaprine.
ButacaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cyclobenzaprine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Cyclobenzaprine.
CaffeineThe metabolism of Cyclobenzaprine can be decreased when combined with Caffeine.
CandoxatrilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Candoxatril.
CaptoprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Captopril.
CarbamazepineThe metabolism of Cyclobenzaprine can be increased when combined with Carbamazepine.
CarbamazepineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Carfentanil.
CariprazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Carisoprodol.
CaroxazoneCyclobenzaprine may increase the serotonergic activities of Caroxazone.
CelecoxibThe metabolism of Cyclobenzaprine can be decreased when combined with Celecoxib.
CeliprololThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Celiprolol.
CeritinibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cyclobenzaprine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chloroprocaine.
ChloroquineThe metabolism of Cyclobenzaprine can be decreased when combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorphenamine.
ChlorphentermineCyclobenzaprine may increase the stimulatory activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorpromazine.
ChlorpromazineThe metabolism of Cyclobenzaprine can be decreased when combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Cyclobenzaprine can be decreased when combined with Cholecalciferol.
ChymostatinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Chymostatin.
CilastatinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Cilastatin.
CilazaprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Cilazapril.
CimetidineThe metabolism of Cyclobenzaprine can be decreased when combined with Cimetidine.
CinacalcetThe serum concentration of Cyclobenzaprine can be increased when it is combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Cyclobenzaprine.
CirazolineCyclobenzaprine may increase the vasopressor activities of Cirazoline.
CitalopramThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Citalopram.
CitalopramThe metabolism of Cyclobenzaprine can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Cyclobenzaprine can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Cyclobenzaprine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clemastine.
ClenbuterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clenbuterol.
ClidiniumThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clidinium.
ClobazamThe metabolism of Cyclobenzaprine can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clomipramine.
ClomipramineThe metabolism of Cyclobenzaprine can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clonazepam.
ClonidineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Cyclobenzaprine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Cyclobenzaprine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cyclobenzaprine.
ClotrimazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clozapine.
ClozapineThe metabolism of Cyclobenzaprine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Cyclobenzaprine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Cyclobenzaprine.
ConivaptanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Cyclobenzaprine can be decreased when combined with Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cyclizine.
CyclosporineThe metabolism of Cyclobenzaprine can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Cyclobenzaprine can be increased when it is combined with Dabigatran etexilate.
DabrafenibThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Cyclobenzaprine.
DarifenacinThe metabolism of Cyclobenzaprine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Cyclobenzaprine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desflurane.
DesipramineThe metabolism of Cyclobenzaprine can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desloratadine.
DesmopressinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Detomidine.
DexamethasoneThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dexbrompheniramine.
DexmedetomidineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Cyclobenzaprine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Cyclobenzaprine.
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Cyclobenzaprine.
DextroamphetamineCyclobenzaprine may increase the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Cyclobenzaprine.
DextromoramideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cyclobenzaprine.
DezocineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Cyclobenzaprine.
DicoumarolCyclobenzaprine may increase the anticoagulant activities of Dicoumarol.
DifenoxinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dihydrocodeine.
DihydroergotamineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Cyclobenzaprine.
DihydroergotamineThe metabolism of Cyclobenzaprine can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dihydromorphine.
DiltiazemThe metabolism of Cyclobenzaprine can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Cyclobenzaprine can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Diphenoxylate.
DipivefrinThe therapeutic efficacy of Dipivefrin can be decreased when used in combination with Cyclobenzaprine.
DobutamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dobutamine.
DolasetronDolasetron may increase the serotonergic activities of Cyclobenzaprine.
DoramectinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Doxepin.
DoxycyclineThe metabolism of Cyclobenzaprine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.
DoxylamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.
DronedaroneThe metabolism of Cyclobenzaprine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Drotebanol.
DroxidopaThe therapeutic efficacy of Droxidopa can be decreased when used in combination with Cyclobenzaprine.
DuloxetineThe metabolism of Cyclobenzaprine can be decreased when combined with Duloxetine.
DuloxetineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Cyclobenzaprine.
EcabetThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ecabet.
EcgonineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with ECGONINE METHYL ESTER.
EdoxabanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Edoxaban.
EfavirenzThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Efavirenz.
ElafinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Elafin.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Cyclobenzaprine.
EliglustatThe metabolism of Cyclobenzaprine can be decreased when combined with Eliglustat.
EnalaprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Enalapril.
EnalaprilatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Enalaprilat.
EnalkirenThe serum concentration of Cyclobenzaprine can be increased when it is combined with Enalkiren.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Cyclobenzaprine.
EntacaponeThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Entacapone.
EnzalutamideThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Enzalutamide.
EphedraThe therapeutic efficacy of Ephedra can be decreased when used in combination with Cyclobenzaprine.
EpinephrineThe therapeutic efficacy of Epinephrine can be decreased when used in combination with Cyclobenzaprine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ergoloid mesylate.
ErgonovineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ergonovine.
ErgotamineCyclobenzaprine may increase the vasopressor activities of Ergotamine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Cyclobenzaprine.
ErythromycinThe metabolism of Cyclobenzaprine can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Cyclobenzaprine.
EthanolCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Cyclobenzaprine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cyclobenzaprine.
EthosuximideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethotoin.
Ethyl biscoumacetateCyclobenzaprine may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etizolam.
EtomidateThe therapeutic efficacy of Etomidate can be decreased when used in combination with Cyclobenzaprine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Cyclobenzaprine.
EtoperidoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etorphine.
EtravirineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fenfluramine.
FenoterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fenoterol.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyclobenzaprine.
FexofenadineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Flibanserin.
FluconazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Cyclobenzaprine.
FlupentixolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Cyclobenzaprine.
FluspirileneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fluvoxamine.
FluvoxamineThe metabolism of Cyclobenzaprine can be decreased when combined with Fluvoxamine.
FormoterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Formoterol.
FosamprenavirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Cyclobenzaprine can be increased when it is combined with Fosaprepitant.
FosinoprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Frovatriptan.
FurazolidoneCyclobenzaprine may increase the serotonergic activities of Furazolidone.
Fusidic AcidThe serum concentration of Cyclobenzaprine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Gamma Hydroxybutyric Acid.
GeldanamycinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Geldanamycin.
GlutethimideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Glutethimide.
GM6001The serum concentration of Cyclobenzaprine can be increased when it is combined with GM6001.
GranisetronGranisetron may increase the serotonergic activities of Cyclobenzaprine.
GuanabenzThe therapeutic efficacy of Guanabenz can be decreased when used in combination with Cyclobenzaprine.
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Cyclobenzaprine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Cyclobenzaprine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Cyclobenzaprine.
HaloperidolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Haloperidol.
HaloperidolThe metabolism of Cyclobenzaprine can be decreased when combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Hexobarbital.
HirulogThe serum concentration of Cyclobenzaprine can be increased when it is combined with Hirulog.
HydracarbazineCyclobenzaprine may increase the serotonergic activities of Hydracarbazine.
HydrocodoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclobenzaprine.
Hydroxyamphetamine hydrobromideCyclobenzaprine may increase the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.
HydroxyzineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Hydroxyzine.
IdelalisibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Iloperidone.
ImatinibThe metabolism of Cyclobenzaprine can be decreased when combined with Imatinib.
ImipramineThe metabolism of Cyclobenzaprine can be decreased when combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Imipramine.
IndacaterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Indacaterol.
IndalpineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Indalpine.
IndinavirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Indinavir.
IproclozideCyclobenzaprine may increase the serotonergic activities of Iproclozide.
IproniazidCyclobenzaprine may increase the serotonergic activities of Iproniazid.
IsavuconazoniumThe metabolism of Cyclobenzaprine can be decreased when combined with Isavuconazonium.
IsocarboxazidCyclobenzaprine may increase the serotonergic activities of Isocarboxazid.
IsoetarineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Isoetarine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Cyclobenzaprine.
IsoflurophateThe serum concentration of Cyclobenzaprine can be increased when it is combined with Isoflurophate.
IsoniazidThe metabolism of Cyclobenzaprine can be decreased when combined with Isoniazid.
IsoprenalineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Isoprenaline.
IsradipineThe metabolism of Cyclobenzaprine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ivacaftor.
IxazomibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ixazomib.
KetamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ketobemidone.
KetoconazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lamotrigine.
LepirudinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Lepirudin.
LevetiracetamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cyclobenzaprine.
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Cyclobenzaprine.
LidocaineThe metabolism of Cyclobenzaprine can be decreased when combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lidocaine.
LinagliptinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Linagliptin.
LinezolidLinezolid may increase the serotonergic activities of Cyclobenzaprine.
LinezolidThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Linezolid.
LiothyronineLiothyronine may increase the arrhythmogenic activities of Cyclobenzaprine.
LiotrixLiotrix may increase the arrhythmogenic activities of Cyclobenzaprine.
LisdexamfetamineCyclobenzaprine may increase the stimulatory activities of Lisdexamfetamine.
LisinoprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lofentanil.
LofexidineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Cyclobenzaprine.
LopinavirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Cyclobenzaprine.
LorcaserinThe metabolism of Cyclobenzaprine can be decreased when combined with Lorcaserin.
LorcaserinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lorcaserin.
LovastatinThe metabolism of Cyclobenzaprine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lu AA21004.
LuliconazoleThe serum concentration of Cyclobenzaprine can be increased when it is combined with Luliconazole.
LumefantrineThe metabolism of Cyclobenzaprine can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Maprotiline.
MebanazineCyclobenzaprine may increase the serotonergic activities of Mebanazine.
MeclizineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Melperone.
MephentermineCyclobenzaprine may increase the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cyclobenzaprine.
MesoridazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Mesoridazine.
MetaraminolCyclobenzaprine may increase the vasopressor activities of Metaraminol.
MetaxaloneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Metaxalone.
MethadoneThe metabolism of Cyclobenzaprine can be decreased when combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methadyl Acetate.
MethamphetamineCyclobenzaprine may increase the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Cyclobenzaprine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methotrimeprazine.
MethoxamineCyclobenzaprine may increase the vasopressor activities of Methoxamine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methsuximide.
Methylene blueCyclobenzaprine may increase the serotonergic activities of Methylene blue.
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Cyclobenzaprine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Cyclobenzaprine.
MetoclopramideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Metoclopramide.
MetoprololThe metabolism of Cyclobenzaprine can be decreased when combined with Metoprolol.
MetyrosineCyclobenzaprine may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Cyclobenzaprine.
MexiletineThe metabolism of Cyclobenzaprine can be decreased when combined with Mexiletine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Cyclobenzaprine.
MidodrineCyclobenzaprine may increase the vasopressor activities of Midodrine.
MifepristoneThe metabolism of Cyclobenzaprine can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Milnacipran.
MinaprineCyclobenzaprine may increase the serotonergic activities of Minaprine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.
MirabegronThe metabolism of Cyclobenzaprine can be decreased when combined with Mirabegron.
MirtazapineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Cyclobenzaprine.
MitotaneThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Mitotane.
MoclobemideCyclobenzaprine may increase the serotonergic activities of Moclobemide.
ModafinilThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Modafinil.
MoexiprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Cyclobenzaprine.
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Cyclobenzaprine.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Cyclobenzaprine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.
NabiloneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Nabilone.
NafcillinThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cyclobenzaprine.
NaphazolineThe therapeutic efficacy of Naphazoline can be decreased when used in combination with Cyclobenzaprine.
NaratriptanThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Naratriptan.
NCX 4016The serum concentration of Cyclobenzaprine can be increased when it is combined with NCX 4016.
NefazodoneThe metabolism of Cyclobenzaprine can be decreased when combined with Nefazodone.
NefazodoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Nefazodone.
NelfinavirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Cyclobenzaprine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Cyclobenzaprine can be decreased when combined with Nevirapine.
NialamideCyclobenzaprine may increase the serotonergic activities of Nialamide.
NicardipineThe metabolism of Cyclobenzaprine can be decreased when combined with Nicardipine.
NicorandilCyclobenzaprine may increase the hypotensive activities of Nicorandil.
NilotinibThe metabolism of Cyclobenzaprine can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Nitrous oxide.
NorepinephrineThe therapeutic efficacy of Norepinephrine can be decreased when used in combination with Cyclobenzaprine.
NormethadoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Nortriptyline.
OctamoxinCyclobenzaprine may increase the serotonergic activities of Octamoxin.
OlanzapineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Olanzapine.
OlaparibThe metabolism of Cyclobenzaprine can be decreased when combined with Olaparib.
OlodaterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Olodaterol.
OlopatadineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Olopatadine.
OmapatrilatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Omapatrilat.
OndansetronThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Cyclobenzaprine.
OpiumThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Opium.
OrciprenalineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Orciprenaline.
OrphenadrineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Cyclobenzaprine.
OsanetantThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Osanetant.
OsimertinibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Osimertinib.
OtamixabanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Otamixaban.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Cyclobenzaprine.
OxprenololThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Cyclobenzaprine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cyclobenzaprine.
OxymetazolineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Cyclobenzaprine.
OxymorphoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Oxymorphone.
PalbociclibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Palbociclib.
PaliperidoneThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Cyclobenzaprine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Cyclobenzaprine.
PalonosetronPalonosetron may increase the serotonergic activities of Cyclobenzaprine.
PanobinostatThe metabolism of Cyclobenzaprine can be decreased when combined with Panobinostat.
ParaldehydeCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Cyclobenzaprine.
PargylineCyclobenzaprine may increase the serotonergic activities of Pargyline.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Cyclobenzaprine.
Peginterferon alfa-2bThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Peginterferon alfa-2b.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclobenzaprine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Cyclobenzaprine.
PerampanelThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Perampanel.
PergolideThe therapeutic efficacy of Pergolide can be decreased when used in combination with Cyclobenzaprine.
PerindoprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cyclobenzaprine.
PhenelzineCyclobenzaprine may increase the serotonergic activities of Phenelzine.
PhenindioneCyclobenzaprine may increase the anticoagulant activities of Phenindione.
PheniprazineCyclobenzaprine may increase the serotonergic activities of Pheniprazine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Phenoxyethanol.
PhenoxypropazineCyclobenzaprine may increase the serotonergic activities of Phenoxypropazine.
PhenprocoumonCyclobenzaprine may increase the anticoagulant activities of Phenprocoumon.
PhentermineCyclobenzaprine may increase the stimulatory activities of Phentermine.
PhenylephrineCyclobenzaprine may increase the vasopressor activities of Phenylephrine.
PhenylpropanolamineThe therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Cyclobenzaprine.
PhenytoinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Phenytoin.
PhosphoramidonThe serum concentration of Cyclobenzaprine can be increased when it is combined with Phosphoramidon.
PimozideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pipotiazine.
PirbuterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pirbuterol.
PirlindoleCyclobenzaprine may increase the serotonergic activities of Pirlindole.
PivhydrazineCyclobenzaprine may increase the serotonergic activities of Pivhydrazine.
PizotifenThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pomalidomide.
PosaconazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Posaconazole.
PramipexoleCyclobenzaprine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Cyclobenzaprine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Cyclobenzaprine.
PrimidoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Primidone.
PrinomastatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Prinomastat.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Cyclobenzaprine.
ProcarbazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Procarbazine.
ProcaterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Procaterol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Promazine.
PromazineThe metabolism of Cyclobenzaprine can be decreased when combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Cyclobenzaprine.
PropericiazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Cyclobenzaprine.
PropoxycaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with PSD502.
PseudoephedrineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Cyclobenzaprine.
QuazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Quetiapine.
QuinaprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Quinapril.
QuinidineCyclobenzaprine may increase the QTc-prolonging activities of Quinidine.
QuinidineThe metabolism of Cyclobenzaprine can be decreased when combined with Quinidine.
QuinineThe metabolism of Cyclobenzaprine can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ramelteon.
RamiprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ramipril.
RanolazineThe metabolism of Cyclobenzaprine can be decreased when combined with Ranolazine.
RasagilineCyclobenzaprine may increase the serotonergic activities of Rasagiline.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cyclobenzaprine.
RemikirenThe serum concentration of Cyclobenzaprine can be increased when it is combined with Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Reserpine.
RifabutinThe metabolism of Cyclobenzaprine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Cyclobenzaprine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Cyclobenzaprine can be increased when combined with Rifapentine.
RisperidoneThe therapeutic efficacy of Risperidone can be decreased when used in combination with Cyclobenzaprine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Cyclobenzaprine.
RitodrineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ritodrine.
RitonavirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Rivaroxaban.
RizatriptanThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Rizatriptan.
RolapitantThe metabolism of Cyclobenzaprine can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Romifidine.
RopiniroleCyclobenzaprine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Cyclobenzaprine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Cyclobenzaprine.
RotigotineCyclobenzaprine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Cyclobenzaprine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with S-Ethylisothiourea.
SafrazineCyclobenzaprine may increase the serotonergic activities of Safrazine.
SalbutamolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Salbutamol.
SalmeterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Salmeterol.
SaquinavirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cyclobenzaprine.
SelegilineCyclobenzaprine may increase the serotonergic activities of Selegiline.
SertindoleThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sertraline.
SertralineThe metabolism of Cyclobenzaprine can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sevoflurane.
SildenafilThe metabolism of Cyclobenzaprine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sodium oxybate.
SpiraprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Spirapril.
St. John's WortThe serum concentration of Cyclobenzaprine can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclobenzaprine.
SulfisoxazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Cyclobenzaprine.
SuvorexantThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tasimelteon.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Cyclobenzaprine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Telaprevir.
TelithromycinThe metabolism of Cyclobenzaprine can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Cyclobenzaprine.
TemocaprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Temocapril.
TenofovirThe metabolism of Cyclobenzaprine can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Cyclobenzaprine can be decreased when combined with Terbinafine.
TerbutalineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Terbutaline.
TeriflunomideThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tetrodotoxin.
ThalidomideCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Cyclobenzaprine.
TheophyllineThe metabolism of Cyclobenzaprine can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Cyclobenzaprine.
ThioproperazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Thioproperazine.
ThioridazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Thioridazine.
ThiorphanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Thiorphan.
ThiothixeneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Thiothixene.
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Cyclobenzaprine.
TiagabineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tiagabine.
TiclopidineThe metabolism of Cyclobenzaprine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tiletamine.
TipranavirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Tipranavir.
TizanidineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Cyclobenzaprine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Cyclobenzaprine.
TocilizumabThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tolcapone.
ToloxatoneCyclobenzaprine may increase the serotonergic activities of Toloxatone.
TopiramateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Cyclobenzaprine.
TrandolaprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Trandolapril.
Trans-2-PhenylcyclopropylamineCyclobenzaprine may increase the serotonergic activities of Trans-2-Phenylcyclopropylamine.
TranylcypromineCyclobenzaprine may increase the serotonergic activities of Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Cyclobenzaprine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Triflupromazine.
TrimipramineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Triprolidine.
UbenimexThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ubenimex.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Cyclobenzaprine.
VemurafenibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Cyclobenzaprine can be decreased when combined with Venlafaxine.
VenlafaxineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Venlafaxine.
VerapamilThe metabolism of Cyclobenzaprine can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Vigabatrin.
VilanterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Vilanterol.
VilazodoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Vilazodone.
VildagliptinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Vildagliptin.
VoriconazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Vortioxetine.
WarfarinCyclobenzaprine may increase the anticoagulant activities of Warfarin.
XimelagatranThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ximelagatran.
XylazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Xylazine.
XylometazolineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Cyclobenzaprine.
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Cyclobenzaprine.
ZaleplonThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ziprasidone.
ZiprasidoneThe metabolism of Cyclobenzaprine can be decreased when combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Cyclobenzaprine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Cyclobenzaprine.
ZonisamideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Honda M, Nishida T, Ono H: Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT(2) receptors. Eur J Pharmacol. 2003 Jan 1;458(1-2):91-9. [PubMed:12498911 ]
  2. Kobayashi H, Hasegawa Y, Ono H: Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems. Eur J Pharmacol. 1996 Sep 5;311(1):29-35. [PubMed:8884233 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Wang RW, Liu L, Cheng H: Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91. [PubMed:8818577 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Wang RW, Liu L, Cheng H: Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91. [PubMed:8818577 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 31, 2016 02:13